On July 2, XtalPi Holdings rose 5.1% in regular trading, trading at HKD 7.8/share, with turnover of HKD 291 million.
On the news front, the company has recently seen a cluster of positive developments. Its AI autonomous experiment workstation was officially deployed at Sinopec, marking substantial progress in extending its AI+robotics platform into materials science. Earlier, the company announced a strategic AI drug discovery partnership with a leading international pharmaceutical company valued at over USD 400 million, focusing on oral small-molecule therapies targeting GPCR. Additionally, a USD 100 million share buyback program has been underway since June 10, signaling management confidence in the company's intrinsic value.
The broader life sciences sector rallied on the same day, with GenScript Biotech up 3.84%, WuXi Biologics up 3.06%, and WuXi XDC up 2.8%, providing additional momentum through sector-wide strength.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)